Incidence and Survival of Children and Adolescents With Wilms Tumor, United States, 2001–2020
ABSTRACT Background Wilms tumor (WT) is the most common pediatric malignancy of the kidney. Past studies describing WT incidence and survival used surveillance data with < 30% of the US population. We evaluated differences in WT incidence and survival comparing demographic groups and tumor charac...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Cancer Medicine |
| Online Access: | https://doi.org/10.1002/cam4.70598 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849424727325540352 |
|---|---|
| author | Andres F. Espinoza Ekene Onwuka David A. Siegel Shifan Dai Sanjeev A. Vasudevan Michael E. Scheurer Philip J. Lupo |
| author_facet | Andres F. Espinoza Ekene Onwuka David A. Siegel Shifan Dai Sanjeev A. Vasudevan Michael E. Scheurer Philip J. Lupo |
| author_sort | Andres F. Espinoza |
| collection | DOAJ |
| description | ABSTRACT Background Wilms tumor (WT) is the most common pediatric malignancy of the kidney. Past studies describing WT incidence and survival used surveillance data with < 30% of the US population. We evaluated differences in WT incidence and survival comparing demographic groups and tumor characteristics. Methods We analyzed new cases of WT among patients aged < 20 years at diagnosis by using incidence data from US Cancer Statistics (USCS) for 2003–2020 and 5‐year relative survival (RS) data from the National Program of Cancer Registries (NPCR) for 2001–2019. To assess incidence trends, average annual percent change (AAPC) was calculated by using joinpoint regression. Relative survival (RS) and all‐cause survival were calculated overall and by demographic and clinical variables. Results During 2003–2020, 8218 cases of WT were reported in USCS, which represented an age‐adjusted incidence rate of 5.7 cases per million. Rates were the highest among females (6.3), children aged 0–4 years (17.2), and non‐Hispanic Black patients (7.1). Overall, trends remained stable (AAPC = −0.4, 95% CI: −1.4 to 0.4). Among 7567 cases of WT in NPCR, 5‐year RS was 92.6%. Patients with the lowest survival include the following: those aged 10–19 years (hazard ratio [HR] = 1.65, 95% CI: 1.02–2.65); non‐Hispanic Black patients (HR = 1.39, 95% CI: 1.11–1.76); those with regional stage (HR = 1.93, 95% CI: 1.47–2.54) or distant stage (HR = 5.12, 95% CI: 3.99–6.57); and patients from nonmetropolitan counties (HR = 1.46, 95% CI: 1.09–1.96). Individuals diagnosed during 2011–2019 (HR = 0.64, 95% CI: 0.53–0.77) had higher survival than those diagnosed during 2001–2010. Conclusions The highest WT incidence rates were patients who were female, 0–4 years, and non‐Hispanic Black. Survival improved during the study period; survival differed by race, ethnicity, metropolitan status, and age. Further studies to delineate the causes of these disparities may improve outcomes. |
| format | Article |
| id | doaj-art-0588de570e7546a4a0d632b7c5e99d6d |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-0588de570e7546a4a0d632b7c5e99d6d2025-08-20T03:30:02ZengWileyCancer Medicine2045-76342025-02-01143n/an/a10.1002/cam4.70598Incidence and Survival of Children and Adolescents With Wilms Tumor, United States, 2001–2020Andres F. Espinoza0Ekene Onwuka1David A. Siegel2Shifan Dai3Sanjeev A. Vasudevan4Michael E. Scheurer5Philip J. Lupo6Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Texas Children's Surgical Oncology Program and Liver Tumor Program, Dan L. Duncan Cancer Center Baylor College of Medicine Houston Texas USADivisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Texas Children's Surgical Oncology Program and Liver Tumor Program, Dan L. Duncan Cancer Center Baylor College of Medicine Houston Texas USADivision of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention Atlanta Georgia USACyberdata Technologies Inc. Herndon Virginia USADivisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Texas Children's Surgical Oncology Program and Liver Tumor Program, Dan L. Duncan Cancer Center Baylor College of Medicine Houston Texas USADepartment of Pediatrics, Hematology‐Oncology Section, Texas Children's Hospital, Dan L. Duncan Cancer Center Baylor College of Medicine Houston Texas USADepartment of Pediatrics, Hematology‐Oncology Section, Texas Children's Hospital, Dan L. Duncan Cancer Center Baylor College of Medicine Houston Texas USAABSTRACT Background Wilms tumor (WT) is the most common pediatric malignancy of the kidney. Past studies describing WT incidence and survival used surveillance data with < 30% of the US population. We evaluated differences in WT incidence and survival comparing demographic groups and tumor characteristics. Methods We analyzed new cases of WT among patients aged < 20 years at diagnosis by using incidence data from US Cancer Statistics (USCS) for 2003–2020 and 5‐year relative survival (RS) data from the National Program of Cancer Registries (NPCR) for 2001–2019. To assess incidence trends, average annual percent change (AAPC) was calculated by using joinpoint regression. Relative survival (RS) and all‐cause survival were calculated overall and by demographic and clinical variables. Results During 2003–2020, 8218 cases of WT were reported in USCS, which represented an age‐adjusted incidence rate of 5.7 cases per million. Rates were the highest among females (6.3), children aged 0–4 years (17.2), and non‐Hispanic Black patients (7.1). Overall, trends remained stable (AAPC = −0.4, 95% CI: −1.4 to 0.4). Among 7567 cases of WT in NPCR, 5‐year RS was 92.6%. Patients with the lowest survival include the following: those aged 10–19 years (hazard ratio [HR] = 1.65, 95% CI: 1.02–2.65); non‐Hispanic Black patients (HR = 1.39, 95% CI: 1.11–1.76); those with regional stage (HR = 1.93, 95% CI: 1.47–2.54) or distant stage (HR = 5.12, 95% CI: 3.99–6.57); and patients from nonmetropolitan counties (HR = 1.46, 95% CI: 1.09–1.96). Individuals diagnosed during 2011–2019 (HR = 0.64, 95% CI: 0.53–0.77) had higher survival than those diagnosed during 2001–2010. Conclusions The highest WT incidence rates were patients who were female, 0–4 years, and non‐Hispanic Black. Survival improved during the study period; survival differed by race, ethnicity, metropolitan status, and age. Further studies to delineate the causes of these disparities may improve outcomes.https://doi.org/10.1002/cam4.70598 |
| spellingShingle | Andres F. Espinoza Ekene Onwuka David A. Siegel Shifan Dai Sanjeev A. Vasudevan Michael E. Scheurer Philip J. Lupo Incidence and Survival of Children and Adolescents With Wilms Tumor, United States, 2001–2020 Cancer Medicine |
| title | Incidence and Survival of Children and Adolescents With Wilms Tumor, United States, 2001–2020 |
| title_full | Incidence and Survival of Children and Adolescents With Wilms Tumor, United States, 2001–2020 |
| title_fullStr | Incidence and Survival of Children and Adolescents With Wilms Tumor, United States, 2001–2020 |
| title_full_unstemmed | Incidence and Survival of Children and Adolescents With Wilms Tumor, United States, 2001–2020 |
| title_short | Incidence and Survival of Children and Adolescents With Wilms Tumor, United States, 2001–2020 |
| title_sort | incidence and survival of children and adolescents with wilms tumor united states 2001 2020 |
| url | https://doi.org/10.1002/cam4.70598 |
| work_keys_str_mv | AT andresfespinoza incidenceandsurvivalofchildrenandadolescentswithwilmstumorunitedstates20012020 AT ekeneonwuka incidenceandsurvivalofchildrenandadolescentswithwilmstumorunitedstates20012020 AT davidasiegel incidenceandsurvivalofchildrenandadolescentswithwilmstumorunitedstates20012020 AT shifandai incidenceandsurvivalofchildrenandadolescentswithwilmstumorunitedstates20012020 AT sanjeevavasudevan incidenceandsurvivalofchildrenandadolescentswithwilmstumorunitedstates20012020 AT michaelescheurer incidenceandsurvivalofchildrenandadolescentswithwilmstumorunitedstates20012020 AT philipjlupo incidenceandsurvivalofchildrenandadolescentswithwilmstumorunitedstates20012020 |